Megha Manchanda &Amp; Sohini Das

Stories by Megha Manchanda &Amp; Sohini Das

Covishield volunteer decides to move court against Serum Institute

Covishield volunteer decides to move court against Serum Institute

Rediff.com   11 Dec 2020

'Our client is suffering due to the ill-effects of the vaccine. He has to be compensated for his suffering. Further, a detailed investigation has to be done on the Covishield vaccine and its side-effects,' says the volunteer's advocate.

Why Modi visited Serum's Covid vaccine unit

Why Modi visited Serum's Covid vaccine unit

Rediff.com   10 Dec 2020

The PM's visit would signal a strong intent towards making sure India becomes a beneficiary as vaccines become a massively traded commodity in the coming years.

Serum Institute set to sign deal with Centre for Covishield

Serum Institute set to sign deal with Centre for Covishield

Rediff.com   9 Dec 2020

By January-February, it's expected to have at least 100 million doses for the Indian government, reports Sohini Das.

How Indian pharma bounced back from lockdown lows

How Indian pharma bounced back from lockdown lows

Rediff.com   7 Dec 2020

From rising prescriptions to the pharma sales force back on the field with full vigour and companies finally finding their feet with the digital marketing strategies - Indian drug makers have shown that medicine sales is certainly a sunshine sector.

Covid: How Pfizer plans to resolve cold storage issues in India

Covid: How Pfizer plans to resolve cold storage issues in India

Rediff.com   7 Dec 2020

The company has developed detailed logistical plans and tools to support effective vaccine transport, storage, and temperature monitoring. Sohini Das and Ruchika Chitravanshi report.

Vodafone Idea hikes tariff as it struggles to pay dues

Vodafone Idea hikes tariff as it struggles to pay dues

Rediff.com   2 Dec 2020

The latest move, even if it is symbolic, is the first rate hike after the one announced end of 2019.

How states are preparing for Covid vaccine distribution

How states are preparing for Covid vaccine distribution

Rediff.com   2 Dec 2020

Each state has its own weak areas that need attention. Some states have already identified the gaps and sought the Centre's help. Vinay Umarji, Ishita Ayan Dutt, Samreen Ahmad and Sohini Das report.

India may get first Covid-19 vaccine by February

India may get first Covid-19 vaccine by February

Rediff.com   30 Nov 2020

The government plans to immunise 30 million people in the first phase, starting February, and by July, the target is to vaccinate 250 million people, reports Sohini Das.

Why your Uber/Ola surge prices won't soar anymore

Why your Uber/Ola surge prices won't soar anymore

Rediff.com   28 Nov 2020

New norms issued as per the Motor Vehicle Aggregator Guidelines 2020 have mandated a cap on surge price, preventing aggregators from charging more than 1.5 times of the base fare.

Indian Immunologicals to set up new vaccine plant, raise capacity by 35%

Indian Immunologicals to set up new vaccine plant, raise capacity by 35%

Rediff.com   26 Nov 2020

The company has a pipeline of viral vaccines including Zika, dengue, varicella, as well as a potential Covid-19 inoculation.

BSNL to start telecom services in Mumbai and Delhi from January 1

BSNL to start telecom services in Mumbai and Delhi from January 1

Rediff.com   20 Nov 2020

BSNL will start providing telecom services, both wireless and fixed line, in Mumbai and Delhi on behalf of MTNL from January 1 on a pilot basis for five to six months.

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Rediff.com   13 Nov 2020

'SII has started stockpiling the vaccine and now has roughly 40 million doses ready. It is using some of the capacities it had for under development products for the COVID-19 vaccine and by January we will have a capacity to make 100 million doses per month and a stockpile of 200 million doses.'

Pandemic pushes up demand for CT scanners; firms gear up to meet surge

Pandemic pushes up demand for CT scanners; firms gear up to meet surge

Rediff.com   4 Nov 2020

Siemens Healthineers, one of the largest manufacturers of made-in-India CT scanners, has sold 80-100 such machines in the last 45 days. The medical technology firm typically sells 250 machines in a year.

Bharat Biotech starts Covaxin's at-risk manufacture

Bharat Biotech starts Covaxin's at-risk manufacture

Rediff.com   2 Nov 2020

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.

Why Nitin Gadkari is angry with Highway Authority

Why Nitin Gadkari is angry with Highway Authority

Rediff.com   30 Oct 2020

At the heart of his criticism is the delay in decision making and a lack of monitoring. Some officials, however, blamed the delays on overambitious contractors.

Bharti Airtel to stay away from 5G auctions

Bharti Airtel to stay away from 5G auctions

Rediff.com   29 Oct 2020

Airtel CEO said, the 5G ecosystem is yet to develop in India and the prices are very high. Telecom companies including Vodafone Idea (VI) and Reliance Jio have also said that the current prices are exorbitant.

Why Dr Reddy's had to shut all its units

Why Dr Reddy's had to shut all its units

Rediff.com   25 Oct 2020

Security breach came days after the firm got approval to conduct trials for Covid-19 vaccine candidate Sputnik V.

Covid-19 impact: Low interest loans likely for vaccine companies

Covid-19 impact: Low interest loans likely for vaccine companies

Rediff.com   10 Oct 2020

While there has been no commitment from the government on the procurement of vaccines, initial volumes, or distribution plans, there is a likelihood that the low interest loans may be made available to these players only when the time to scale up manufacturing arises.

Covaxin: How Bharat Biotech plans to boost immunity

Covaxin: How Bharat Biotech plans to boost immunity

Rediff.com   6 Oct 2020

Adjuvants may be added to a vaccine to produce more antibodies and longer lasting immunity thus minimising the dose of antigen needed.

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

Rediff.com   6 Oct 2020

In India, itolizumab, known by the brand name Alzumab, has been priced at Rs 8,000 per vial. Most patients require four vials for Covid-19 treatment, taking the cost of the therapy to Rs 32,000.